Filing Analysis
Marchex, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notice that an earnings release and conference call will occur on August 12, 2026.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Second quarter ended June 30, 2026
- The company is issuing an Earnings Release (Exhibit 99.1)
- Management will hold a conference call to discuss financial results
- The filing includes non-GAAP financial measures and reconciliations to GAAP
Marchex, Inc. has completed the acquisition of 100% of Archenia, Inc., a performance-based marketing technology company. The transaction was financed through $10 million in convertible promissory notes issued to the sellers, who include the Company's Chairman and Vice Chairman.
🚩 Red Flags
- Related-party transaction: The sellers include the Company's Chairman (Russell C. Horowitz) and Vice Chairman (Michael Arends).
- Significant debt issuance: $10 million in convertible promissory notes creates a direct financial obligation.
- Potential dilution: Convertible notes at $1.80/share and potential earn-out shares represent significant future equity dilution.
📋 Key Facts
- Acquisition of 100% of Archenia, Inc. closed on July 1, 2026.
- Consideration includes $10 million in convertible promissory notes bearing 6% interest.
- Notes are payable in three equal tranches at 12, 18, and 24 months.
- Conversion price for Notes is set at $1.80 per share of Class B common stock.
- Earn-out component: Up to 2 million shares of Class B common stock annually for two years based on revenue/EBITDA and integration targets.
- The transaction received overwhelming shareholder approval (99.9% simple and minority vote).
Marchex, Inc. reported its financial results for the first quarter ended March 31, 2026, and held a corresponding conference call. The filing serves as a formal furnishing of the earnings release and includes reconciliations for non-GAAP financial measures.
📋 Key Facts
- Financial results cover the first quarter ended March 31, 2026.
- Earnings release was furnished as Exhibit 99.1 on May 13, 2026.
- The company utilized non-GAAP financial measures and provided reconciliations to GAAP measures.
- The report was signed by Brian Nagle, Chief Financial Officer.
Marchex, Inc. entered into a definitive agreement to acquire Archenia, Inc. for $10 million in convertible promissory notes plus a potential earn-out of 4 million shares. The transaction is classified as a related-party transaction, as certain sellers are affiliated with Marchex, requiring a special committee and disinterested stockholder approval.
🚩 Red Flags
- Related-party transaction where insiders are the sellers of the acquired company.
- Significant potential dilution from both the $10 million in convertible debt and the 4 million share earn-out.
- The transaction requires a specific vote from disinterested stockholders, highlighting the inherent conflict of interest.
📋 Key Facts
- Base consideration of $10 million in 6% convertible promissory notes issued to Archenia stockholders.
- Notes are payable in three equal tranches on the 12-, 18-, and 24-month anniversaries of closing.
- Notes are convertible into Class B common stock at a fixed price of $1.80 per share.
- Earn-out consideration of up to 4 million shares of Class B common stock based on revenue, Adjusted EBITDA, and integration targets over two years.
- The transaction involves related parties, necessitating a Special Committee of independent directors.
- Craig-Hallum Capital Group LLC provided a fairness opinion regarding the purchase price.
- Closing is contingent upon approval by a majority of disinterested stockholders.
Marchex, Inc. entered into a sublease agreement for its 12,300 square foot Seattle office space with RentSpree, Inc. through September 2027. This transaction triggered a projected $203,000 non-cash impairment charge for the company's right-of-use asset in the first quarter of 2026.
🚩 Red Flags
- Material impairment charge (Item 2.06) indicating the asset's carrying value exceeded fair value.
- Multiple 8-K items (1.01 and 2.06) reported in a single filing.
📋 Key Facts
- Sublease agreement with RentSpree, Inc. for 12,300 sq ft of office space in Seattle, WA.
- The sublease term runs from May 1, 2026, through September 28, 2027.
- Total fixed monthly rent over the term is approximately $337,000.
- Rent starts at $19.25 per square foot, increasing to $19.50 after 12 months.
- A non-cash impairment charge of approximately $203,000 will be recorded in Q1 2026.
Marchex, Inc. entered into a settlement agreement to resolve a civil action, committing to pay a total of $2 million including the release of escrow funds. The settlement was previously anticipated and accrued for in the company's 2025 financial statements.
🚩 Red Flags
- Material cash outflow of $1.75 million for a micro-cap company to resolve litigation.
📋 Key Facts
- Settlement of civil action 'Chris Barnard and Sinc McEvenue v. Marchex, Inc.' in the U.S. District Court for the District of Delaware.
- Total cash payments of $1.75 million scheduled through May 2027.
- Release of $250,000 currently held in escrow by U.S. Bank.
- Payment schedule: $750,000 by May 14, 2026; $500,000 by November 16, 2026; and $500,000 by May 17, 2027.
- The expense was already recorded as an accrual in the 2025 Consolidated Financial Statements.
Marchex, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing includes the earnings release and details regarding a conference call to discuss the results.
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Non-GAAP financial measures were utilized with reconciliations provided in Exhibit 99.1.
- The filing date and report date are March 25, 2026.
Marchex, Inc. announced the approval of restricted stock unit (RSU) grants for three key executives as part of its annual compensation review.
📋 Key Facts
- Grant Date: February 17, 2026.
- Troy Hartless (President & CRO): Granted 128,205 RSUs.
- Francis Feeney (COO, CLO, & Corporate Secretary): Granted 96,153 RSUs.
- Brian Nagle (CFO): Granted 56,089 RSUs.
- Vesting Schedule: All grants vest in full on the first anniversary of the Grant Date (February 17, 2027).
Marchex, Inc. announced the approval of annual cash bonuses for three key executive officers for fiscal year 2025.
📋 Key Facts
- Troy Hartless (President and CRO) approved for a $200,000 bonus.
- Francis Feeney (COO, CLO, and Corporate Secretary) approved for a $150,000 bonus.
- Brian Nagle (CFO) approved for a $40,000 bonus.
- Bonuses pertain to fiscal year 2025 performance.
Marchex, Inc. reported the results of its 2025 annual meeting of stockholders and approved new compensation arrangements for its directors.
📋 Key Facts
- Annual Meeting held on December 16, 2025.
- All five director nominees (Michael Arends, Dennis Cline, Donald Cogsville, Russell Horowitz, M. Wayne Wisehart) were re-elected.
- Ratification of the selection of the Independent Registered Public Accounting Firm was approved with 152,299,333 votes in favor.
- Compensation Committee approved stock option grants of 50,000 options to each director under the 2021 Stock Incentive Plan.
- Options vest over two years (50% annually) and accelerate upon a Change in Control.
- Independent directors will receive $7,500 in cash per quarter for annual board service.
Marchex, Inc. has entered into an Agreement in Principle (AIP) to acquire 100% of Archenia, Inc. for a $10 million convertible promissory note. The transaction involves related parties and requires approval from disinterested stockholders.
🚩 Red Flags
- Related-party transaction: The filing notes that certain Sellers are related parties, necessitating Special Committee oversight.
- Potential dilution: The use of a convertible note and contingent share issuups (up to 4 million shares) poses significant dilution risk to existing shareholders.
- Execution risk: Closing is subject to audited financial statements of the target and stockholder approval.
📋 Key Facts
- Acquisition of 100% of Archenia, Inc. stock via an Agreement in Principle (AIP) dated Nov 13, 2025.
- Consideration consists of a $10 million convertible promissory note with 6% interest.
- Note is payable in three equal tranches on the 12th, 18th, and 24th monthly anniversaries of closing.
- Conversion price set at $1.80 per share (based on 30-day average through Nov 11, 2025).
- Contingent consideration: Up to 4 million total shares of Class B common stock if Archenia meets revenue and Adjusted EBITDA thresholds in the first two years.
- Transaction requires approval by a majority of Marchex’s disinterested stockholders.
- Anticipated closing date is in the first half of 2026.
Marchex, Inc. announced updated compensation arrangements for its top three executive officers, including base salary adjustments and significant new equity grants (stock options and RSUs) effective October 16, 2025.
🚩 Red Flags
- Significant equity dilution potential due to large RSU and option grants to top executives.
📋 Key Facts
- Troy Hartless (President & CRO): Approved annual base salary of $400,000; granted 150,000 stock options and 150,000 RSUs vesting over four years.
- Francis Feeney (COO & CLO): Approved annual base salary of $375,000; granted 150,000 stock options and 150,000 RSUs vesting over four years.
- Brian Nagle (CFO): Approved annual base salary of $275,000; granted 125,000 stock options and 125,000 RSUs vesting over four years.
- Equity Vesting: Options vest quarterly over three years after a one-year cliff; RSUs vest in full on the fourth anniversary of the grant date.
- CFO Severance: Updated terms for Brian Nagle include lump sum payments and COBRA benefits in specific termination/change in control scenarios.
Marchex, Inc. announced a significant leadership overhaul following the resignation of CEO Edwin A. Miller effective September 11, 2025. The company has appointed new President and COO roles, with the existing CRO and CLO serving as Co-Principal Executive Officers.
🚩 Red Flags
- Sudden departure of the CEO.
- Management instability indicated by multiple simultaneous executive appointments/changes.
- Transition to 'Co-Principal Executive Officers' often suggests a period of leadership uncertainty or transition.
📋 Key Facts
- CEO Edwin A. Miller resigned effective September 11, 2025.
- Miller will serve as a consultant for one year with $150,000 annual compensation plus eligibility for his 2025 cash performance bonus.
- Troy Hartless appointed President effective September 15, 2025 (retaining CRO role).
- Francis J. Feeney appointed COO effective September 15, 2025 (retaining CLO role).
- Brian Nagle appointed CFO effective September 15, 2025 (previously SVP, Controller).
- Hartless and Feeney will serve as Co-Principal Executive Officers for SEC reporting purposes.
Marchex, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2025. The filing serves as a formal notice that earnings data and a conference call are being conducted.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 12, 2025.
- The company is providing non-GAAP financial measures and reconciliations in Exhibit 99.1.
- Earnings release was furnished but not 'filed' for purposes of Section 18 liability.
Marchex, Inc. announced its Q1 2025 financial results and the adoption of a new share repurchase program by its Board of Directors.
📋 Key Facts
- Company released financial results for the first quarter ended March 31, 2025.
- Board of Directors adopted a new share repurchase program to buy back up to 3 million shares of Class B common stock.
- Repurchases will be conducted via open market or privately negotiated transactions, including potential Rule 10b5-1 plans.
- The new repurchase program supersedes any previously disclosed programs.
Marchex, Inc. announced the approval of restricted stock unit (RSU) grants for its top executive team as part of an annual compensation review.
📋 Key Facts
- Grant Date: March 20, 2025.
- Edwin Miller (CEO): Granted 106,250 RSUs.
- Troy Hartless (CRO): Granted 87,500 RSUs.
- Brian Nagle (PFO): Granted 7,500 RSUs.
- Vesting Schedule: All grants vest in full on the first anniversary of the Grant Date (March 20, 2026).
- Plan Source: 2021 Stock Incentive Plan.
Marchex, Inc. announced the appointment of Brian Nagle as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective March 6, 2025. The filing also serves to announce the release of Q4 and full-year 2024 financial results.
🚩 Red Flags
- Frequent movement in high-level finance roles (Nagle joined only in August 2024).
📋 Key Facts
- Brian Nagle appointed as Principal Financial Officer and Principal Accounting Officer on March 6, 2025.
- Nagle previously served as SVP, Corporate Controller at Marchex since August 2024.
- Nagle's professional background includes roles at Seekr Technologies, Emergent BioSolutions, and KPMG, LLP.
- The company is issuing a press release regarding financial results for the quarter and year ended December 31, 2024.
Marchex, Inc. announced the termination of Chief Financial Officer Holly Aglio, effective January 10, 2025. Brian Nagle has been appointed as the interim Principal Financial Officer and Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of a CFO in a micro-cap environment can sometimes precede financial scrutiny, though the filing explicitly denies disagreement/misconduct.
📋 Key Facts
- Holly Aglio terminated as CFO on January 10, 2025.
- Departure is stated to be not due to any disagreement, dispute, impropriety, or misconduct.
- Brian Nagle (SVP/Corporate Controller) appointed as Principal Financial Officer and Principal Accounting Officer.
- Aglio will receive severance benefits consistent with prior SEC filings.
Marchex, Inc. announced that Vice Chairman Michael Arends will transition from his board role to a consulting arrangement for the 2025 fiscal year.
🚩 Red Flags
- Significant upfront cash payment ($180,000) to a departing/transitioning director for 'strategic initiatives'.
📋 Key Facts
- Michael Arends (Vice Chairman) to serve as a consultant through Dec 31, 2025.
- Company to pay $180,000 upfront in Q1 2025 for strategic initiatives.
- Grant of 75,000 stock options effective Jan 2, 2025, vesting over two years (50% annually) and upon Change in Control.
- Board service compensation set at $15,000 per quarter.
Marchex, Inc. announced the approval of stock option grants for its directors following the 2024 annual meeting of stockholders. The compensation includes equity vesting over two years and quarterly cash payments for independent directors.
📋 Key Facts
- Grant Date: November 6, 2024
- Compensation Committee approved 50,000 stock options to each director under the 2021 Stock Incentive Plan.
- Exercise price is set at the closing price of Class B common stock on the Grant Date (Nov 6, 2024).
- Options vest over two years: 50% on the first anniversary and 50% on the second anniversary.
- Full vesting occurs upon a Change in Control.
- Independent directors to receive $7,500 in cash per quarter for annual board service.
Marchex, Inc. announced its Q3 2024 financial results and the outcomes of its 2024 Annual Meeting of Stockholders. The company successfully re-elected its entire Board of Directors and received shareholder approval for the ratification of its independent registered public accounting firm.
📋 Key Facts
- Announced Q3 2024 financial results on October 31, 2024 (Item 2.02).
- Held Annual Meeting of Stockholders on October 30, 2024.
- All five director nominees were re-elected: Michael Arends, Dennis Cline, Donald Cogsville, Russell C. Horowitz, and M. Wayne Wisehart.
- Proposal to ratify the selection of the Independent Registered Public Accounting Firm was approved with 150,387,005 votes in favor.
- Class A common stock carries 25 votes per share; Class B common stock carries 1 vote per share.
Marchex, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2024. The filing includes a press release and references non-GAAP financial measures.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 8, 2024.
- The company is issuing a press release (Exhibit 99.1) regarding financial results.
- Management will hold a conference call to discuss the results.
Marchex, Inc. announced new equity incentive grants for its CEO and CRO, alongside updated employment terms that include accelerated vesting and severance provisions triggered by a Change in Control.
🚩 Red Flags
- Accelerated vesting and significant severance packages are highly sensitive to 'Change in Control' events, which can sometimes incentivize management to pursue a sale even if it is not optimal for shareholders.
📋 Key Facts
- On July 26, 2024, the Compensation Committee approved two tranches of stock options for CEO Edwin A. Miller (400,000 total) and CRO Troy Hartless (300,000 total).
- The first tranche vests over four years: 25% on the first anniversary, then quarterly increments of 6.25% over three years.
- A second tranche consists of options that vest in full on the fourth anniversary of the Grant Date.
- All options include accelerated vesting upon a 'Change in Control'.
- Updated employment terms provide for severance (12 months salary/bonus + COBRA) if terminated without Cause or for Good Reason following a Change in Control.
This is an amendment (8-K/A) to a previously filed 8-K, intended solely to correct a clerical error in the EDGAR submission header. The company is correcting the reported Item numbers from Item 1.01 to Items 2.02 and 9.01 to accurately reflect that the filing pertains to quarterly financial results.
🚩 Red Flags
- None identified in this specific amendment; it is a technical correction.
📋 Key Facts
- Filed on May 8, 2024, as Amendment No. 1 to an original filing from May 7, 2024.
- The amendment corrects an 'inadvertent error' in the EDGAR header regarding Item Numbers.
- The correct items being reported are Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- No changes were made to the actual content or disclosures of the original filing.
Marchex, Inc. filed an 8-K to announce its intention to issue a press release and hold a conference call regarding financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Filing date: May 7, 2024.
- The company will provide non-GAAP financial measures and reconciliations in the accompanying press release (Exhibit 99.1).
Marchex, Inc. filed an 8-K to announce the release of its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a placeholder for the upcoming press release and conference call.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: March 14, 2024.
- The company will issue a press release (Exhibit 99.1) containing financial results.
- Management will hold a conference call to discuss the results.